Ignite Creation Date:
2024-10-25 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06648200
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-09
Brief Title:
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer a Single-center Randomized Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
For extensive-stage small cell lung cancer SCLC platinum-chemotherapy cisplatin or carboplatin combined with etoposide as the first-line treatment is recommended However the recurrence rate is extremely high after the initial first-line treatment For those who relapse or progress within more than six minths after the end of the-first-line treatment chose the current guideline recommendation trearment plan has the poor prognosis A new immunotherapeutic strategy is needed to achieve better anti-tumor effects JS004 is a new antibody targeting B and T lymphocyte attenuator BTLA which restrains immune cells function and leads to immune escape of tumor cells The combination of PD-1 and BTLA antibodies has shown a good therapeutic effect in solid tumors This trial aims to investigate the efficacy and safety of the therapeutic regimen of toripalimab and JS004 combined with platinum-based doublet chemotherapy in extensive-stage SCLC or relapsed within more than six months after radical treatment SCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None